242 related articles for article (PubMed ID: 15634651)
1. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Ee PL; He X; Ross DD; Beck WT
Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
[TBL] [Abstract][Full Text] [Related]
2. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
4. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
5. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
6. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
7. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
Wang H; Lee EW; Zhou L; Leung PC; Ross DD; Unadkat JD; Mao Q
Mol Pharmacol; 2008 Mar; 73(3):845-54. PubMed ID: 18042733
[TBL] [Abstract][Full Text] [Related]
10. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
11. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
12. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
[TBL] [Abstract][Full Text] [Related]
13. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
[TBL] [Abstract][Full Text] [Related]
14. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
15. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
16. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Imai Y; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
Jpn J Cancer Res; 2002 Mar; 93(3):231-5. PubMed ID: 11927002
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
18. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
19. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
